Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Valproic acid does not affect markers of human immunodeficiency virus disease progression.

Ances BM, Letendre S, Buzzell M, Marquie-Beck J, Lazaretto D, Marcotte TD, Grant I, Ellis RJ; HNRC Group.

J Neurovirol. 2006 Oct;12(5):403-6.

PMID:
17065134
2.

Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.

Sánchez-Ramón S, Bellón JM, Resino S, Cantó-Nogués C, Gurbindo D, Ramos JT, Muñoz-Fernández MA.

Pediatrics. 2003 Feb;111(2):E168-75.

PMID:
12563091
3.

Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression.

Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM.

AIDS. 2004 May 21;18(8):1101-8.

PMID:
15166525
4.

HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.

Sterling TR, Chaisson RE, Moore RD.

AIDS. 2001 Nov 23;15(17):2251-7.

PMID:
11698698
5.

Cervical dysplasia in women infected with the human immunodeficiency virus (HIV): a correlation with HIV viral load and CD4+ count.

Davis AT, Chakraborty H, Flowers L, Mosunjac MB.

Gynecol Oncol. 2001 Mar;80(3):350-4.

PMID:
11263930
6.

Retinal microangiopathy in human immunodeficiency virus infection is related to higher human immunodeficiency virus-1 load in plasma.

Furrer H, Barloggio A, Egger M, Garweg JG; Swiss HIV Cohort Study.

Ophthalmology. 2003 Feb;110(2):432-6.

PMID:
12578793
7.

Evaluation of human immunodeficiency virus (HIV) type 1 load, CD4 T cell level, and clinical class as time-fixed and time-varying markers of disease progression in HIV-1-infected children.

Kalish LA, McIntosh K, Read JS, Diaz C, Landesman SH, Pitt J, Rich KC, Shearer WT, Davenny K, Lew JF.

J Infect Dis. 1999 Nov;180(5):1514-20. Erratum in: J Infect Dis 2000 Jan;181(1):408.

PMID:
10515810
8.

Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression.

Molina JM, Ferchal F, Chevret S, Barateau V, Poirot C, Morinet F, Modai J.

AIDS. 1994 Jan;8(1):27-33.

PMID:
7912084
9.

Changes in HIV RNA viral load, CD4+ T-cell counts, and levels of immune activation markers associated with anti-tuberculosis therapy and cotrimoxazole prophylaxis among HIV-infected tuberculosis patients in Abidjan, Cote d'Ivoire.

Kalou M, Sassan-Morokro M, Abouya L, Bile C, Maurice C, Maran M, Tossou O, Roels T, Greenberg AE, Wiktor SZ, Nkengasong JN.

J Med Virol. 2005 Feb;75(2):202-8.

PMID:
15602734
10.

MT-2 tropism and CCR-5 genotype strongly influence disease progression in HIV-1-infected individuals.

Bratt G, Leandersson AC, Albert J, Sandström E, Wahren B.

AIDS. 1998 May 7;12(7):729-36.

PMID:
9619804
11.
12.

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.

Mellors JW, Muñoz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, Kingsley LA, Todd JA, Saah AJ, Detels R, Phair JP, Rinaldo CR Jr.

Ann Intern Med. 1997 Jun 15;126(12):946-54.

PMID:
9182471
13.

Close association of CD8+/CD38 bright with HIV-1 replication and complex relationship with CD4+ T-cell count.

Tuaillon E, Al Tabaa Y, Baillat V, Segondy M, Picot MC, Reynes J, Vendrell JP.

Cytometry B Clin Cytom. 2009 Jul;76(4):249-60. doi: 10.1002/cyto.b.20467.

14.

Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.

Price DA, Scullard G, Oxenius A, Braganza R, Beddows SA, Kazmi S, Clarke JR, Johnson GE, Weber JN, Phillips RE.

J Virol. 2003 May;77(10):6041-9.

15.

Ethnicity and discordance in plasma HIV-1 RNA viral load and CD4+ lymphocyte count in a cohort of HIV-1-infected individuals.

Smith PR, Sarner L, Murphy M, James B, Thomas JM, Skinner CJ, Aitken C.

J Clin Virol. 2003 Jan;26(1):101-7.

PMID:
12589840
16.

Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.

Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H.

Scand J Immunol. 2008 Dec;68(6):652-60. doi: 10.1111/j.1365-3083.2008.02184.x.

17.

CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency.

Liu Z, Cumberland WG, Hultin LE, Kaplan AH, Detels R, Giorgi JV.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Aug 1;18(4):332-40.

PMID:
9704938
18.

Combined antiviral therapy reduces HIV-1 plasma load and improves CD4 counts but does not interfere with ongoing lymphocyte apoptosis.

Moretti S, Alesse E, Marcellini S, Di Marzio L, Zazzeroni F, Parroni R, Famularo G, Boschini A, Cifone MG, De Simone C.

Immunopharmacol Immunotoxicol. 1999 Nov;21(4):645-65.

PMID:
10584202
19.

[The prognostic markers of survival and progression in HIV-1 infection. A study of CD4+ lymphocytes, antigen p24 and viral load during 3 years in a cohort of 251 patients].

Rubio Caballero M, Nogués Biau A, Falguera Sacrest M, Puig Ganau T, Lecha N, Rubio Rivas C.

An Med Interna. 2000 Oct;17(10):533-7. Spanish.

PMID:
11109648
20.

Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.

Messele T, Brouwer M, Girma M, Fontanet AL, Miedema F, Hamann D, Rinke de Wit TF.

Clin Immunol. 2001 Feb;98(2):212-9.

PMID:
11161977

Supplemental Content

Support Center